IP Library Patent Application 16814549
Patent Application
App. No. 16/814,549

METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/814,549
Abstract

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.

Claims (17)

1 .- 11 . (canceled)

12 . A method of predicting ammonia exposure for a patient having a urea cycle disorder (UCD) comprising measuring a fasting blood ammonia level for the subject wherein increasing fasting ammonia being associated with higher AUC 0-24 hr and maximum observed ammonia.

13 . The method of claim 12 , wherein ammonia exposure is chosen from daily ammonia burden, average daily ammonia level, and/or highest daily ammonia value.

14 . The method of claim 12 , wherein the blood sample used for measuring fasting blood ammonia levels is a venous blood sample.

15 . The method of claim 12 , wherein the blood sample used for measuring fasting blood ammonia levels is a plasma blood sample.

16 . The method of claim 12 , wherein the fasting blood ammonia level is measured from a fasting morning blood draw.

17 . The method of claim 12 , wherein the fasting period for obtaining a fasting blood ammonia level is 4 hours or more, 5 hours or more, 6 hours or more, 7 hours or more, 8 hours or more, 9 hours or more, 10 hours or more, 11 hours or more, or 12 hours or more.

18 . The method of claim 12 , wherein the fasting period for obtaining a fasting blood ammonia level is 4-8 hours, 6-8 hours, or 8-12 hours.

19 . The method of claim 12 , wherein the fasting period for obtaining a fasting blood ammonia level is overnight.

20 . The method of claim 12 , wherein the upper limit of normal for blood ammonia level is 35 μmol/L.

21 . The method of claim 12 , further comprising comparing the fasting blood ammonia level for the subject with the upper limit of normal for the laboratory.

22 . A kit for determining whether to administer or adjust the dosage of a nitrogen scavenging drug for a subject with a nitrogen retention disorder, wherein the kit comprises:

one or more nitrogen scavenging drugs;

one or more reagents or enzymes to measure blood ammonia levels in a sample; and

optionally other pigments, binders, surfactants, buffers, stabilizers, and/or chemicals necessary to obtain a blood sample and to measure the ammonia level in the sample.

23 . The kit of claim 22 , wherein the one or more reagents comprises bromophenol blue.

24 . The kit of claim 22 , wherein the one or more enzymes includes glutamate dehydrogenase.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS U.S. HOLDING LLC (FKA HORIZON ORPHAN LLC); HZNP LIMITED; HORIZON THERAPEUTICS U.S. HOLDING LLC (SUCCESSOR IN INTEREST TO HORIZON THERAPEUTICS, LLC)
Reel/Frame 065154/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2021
From: MOKHTARANI, MASOUD
To: HORIZON THERAPEUTICS, INC.
Reel/Frame 056355/0460 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2021
From: SCHARSCHMIDT, BRUCE F
To: HORIZON THERAPEUTICS, INC.
Reel/Frame 056355/0593 →
CHANGE OF NAME Recorded May 26, 2021
From: HORIZON THERAPEUTICS, INC.
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 056393/0810 →
SECURITY AGREEMENT Recorded Aug 17, 2020
From: HORIZON ORPHAN LLC; HORIZON THERAPEUTICS, LLC; HZNP LIMITED
To: CITIBANK, N.A.
Reel/Frame 053515/0273 →